LadRx (LADX) AI Stock Analysis

• Market Cap: $5.45K
• Dividend Yield: N/A
• Average Volume (3M): 1.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: N/A
• EPS Growth: -246.39%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.21
• Shares Outstanding: 495,092
• 10 Day Avg. Volume: 91
• 30 Day Avg. Volume: 1,007
• PEG Ratio: <0.01
• Price to Book (P/B): -0.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 109.27
• Enterprise Value/Revenue: 85.97
• Enterprise Value/Gross Profit: 2.32K
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 204
• Revenue Forecast (FY): $113.28M

• Rating: 28 Underperform
• Price Target: ―

LadRx faces significant financial hurdles, with ongoing losses and negative equity highlighting its financial difficulties. The technical indicators suggest a lack of positive momentum, while the negative P/E ratio reflects its unprofitability and lack of income appeal. These factors result in a low overall stock score, underscoring the potential risks for investors.

Positive Factors

Proprietary Technology Platforms

LadRx's focus on proprietary technology platforms provides a competitive edge in developing unique cancer therapeutics, potentially leading to successful commercialization and partnerships.

Partnership Opportunities

LadRx's strategy of forming partnerships and licensing agreements with larger pharmaceutical companies can enhance its market reach and provide necessary financial support for R&D.

No Debt

The absence of debt provides LadRx with some financial flexibility, allowing the company to focus on strategic investments and partnerships without the burden of interest obligations.

Negative Factors

Negative Equity

Negative equity suggests that LadRx is facing financial distress, which could hinder its ability to invest in R&D and commercialize its drug candidates effectively.

Lack of Revenue

The absence of revenue generation highlights the challenge LadRx faces in commercializing its projects, which is critical for sustaining operations and achieving profitability.

Board Member Resignation

The resignation of a board member can signal potential governance issues or strategic disagreements, impacting investor confidence and long-term strategic direction.

LadRx Business Overview & Revenue Model

Company Description

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

How the Company Makes Money

LadRx makes money primarily through the development and commercialization of its proprietary cancer therapeutics. The company generates revenue through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of its drug candidates once they receive regulatory approval. Additionally, LadRx may receive milestone payments and royalties from partner companies that market and distribute its products. The company may also be involved in research collaborations that contribute to its revenue stream.

LadRx Financial Statement Overview

Summary

LadRx is facing significant financial challenges with no revenue generation and persistent losses. The company's negative equity and cash flow issues highlight the need for strategic changes to improve financial health. The biotechnology industry often involves high upfront costs, but the lack of revenue underscores the urgency for successful commercialization of its projects.

Income Statement

LadRx has not generated any revenue over the past few years, indicating a potential challenge in commercializing its biotechnology projects. The company consistently reports significant net losses and negative EBIT/EBITDA margins, reflecting ongoing operational inefficiencies and high expenditure without corresponding income.

Balance Sheet

The balance sheet shows a negative stockholders' equity as of the latest reporting period, indicating potential financial instability. Although there is no debt, negative equity suggests financial distress. The high liabilities relative to assets further exacerbate concerns regarding the company's solvency.

Cash Flow

The company has consistently experienced negative free cash flows, which is a concern for sustainability. Operating cash flows are also negative, indicating cash burn without income. The absence of capital expenditures suggests limited investment in future growth. However, the lack of debt financing provides some flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.92K	0.00	0.00	0.00	0.00	0.00
Gross Profit	257.00	-5.71K	-11.84K	-15.00K	-13.98K	-29.04K
EBITDA	-3.51M	-1.58M	-3.81M	-4.19M	-13.16M	-6.80M
Net Income	-2.50M	-1.59B	400.44K	-4.20M	-13.18M	-6.70M
Balance Sheet
Total Assets	260.07K	839.51K	2.31M	2.25M	8.73M	12.06M
Cash, Cash Equivalents and Short-Term Investments	206.95K	759.74K	2.07M	1.37M	6.77M	10.00M
Total Debt	0.00	0.00	33.61K	229.61K	415.20K	596.30K
Total Liabilities	2.39M	2.26M	2.20M	2.22M	3.95M	3.19M
Stockholders Equity	-2.13M	-1.42M	107.35K	25.72K	4.78M	8.87M
Cash Flow
Free Cash Flow	-1.86B	-1.31B	1.01M	-4.83M	-12.32M	-6.17M
Operating Cash Flow	-1.86B	-1.31B	1.01M	-4.83M	-12.31M	-6.14M
Investing Cash Flow	0.00	0.00	0.00	-766.00	-7.00K	-25.90K
Financing Cash Flow	0.00	0.00	-318.81K	-561.38K	9.08M	39.00K

LadRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LADX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.22, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 26.64 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LADX.

LadRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLRX	44 Neutral	$5.23M	-0.02	-139.55%	―	―	68.08%
BDRX	41 Neutral	$1.44M	-0.03	-60.37%	―	-100.00%	86.75%
SCNI	39 Underperform	$664.23K	-0.07	―	―	178.82%	-4121.10%
OGEN	29 Underperform	$3.58M	-0.05	-168.95%	―	―	90.27%
LADX	28 Underperform	$5.45K	>-0.01	―	―	―	-246.39%